All In Biotech

Drug Trial Radar · NCT01337089

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Last checked: Nov 20, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

660

Actual

Start

Jan 19, 2011

Primary completion

Jan 27, 2016

Study completion Jan 27, 2016

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
First posted
Apr 18, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a six-month open-label extension (OLE) study to evaluate the safety of long-term nabiximols (Sativex®) therapy when used as an adjunctive treatment in participants with advanced cancer. The study provided continued availability of nabiximols to participants who completed a preceding Phase 3 study and new (de novo) participants.

Conditions

  • Pain
  • Advanced Cancer

Interventions

  • NabiximolsDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Of Participants With Treatment-emergent Adverse EventsTime frame: Baseline, Day 183

Locations

128 sites in 18 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    El Cajon, California

  • Site not named

    Gilroy, California

  • Site not named

    Glendale, California

  • Site not named

    Santa Rosa, California

  • Site not named

    Clearwater, Florida

  • Site not named

    Daytona Beach, Florida

  • Site not named

    Holiday, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Lynn Haven, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Stuart, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Winter Park, Florida

  • Site not named

    Marietta, Georgia

  • Site not named

    Newnan, Georgia

  • Site not named

    Stockbridge, Georgia

  • Site not named

    Woodlawn, Illinois

  • Site not named

    Ashland, Kentucky

  • Site not named

    Bossier City, Louisiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Saint Louis Park, Minnesota

  • Site not named

    Kansas City, Missouri

  • Site not named

    Missoula, Montana

  • Site not named

    Berlin, New Jersey

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    Flat Rock, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Cleveland, Ohio

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Houston, Texas

  • Site not named

    Laredo, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Lacey, Washington

  • Site not named

    Parkville, Australia

  • Site not named

    Brussels, Belgium

  • Site not named

    Gabrovo, Bulgaria

Showing 40 of 128 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.